

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Jamp-Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02428237) manufactured by Jamp Pharma Corporation, Septa-Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02428474) manufactured by Septa Pharmaceuticals Inc., Van-Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02438763) manufactured by Vanc Pharmaceuticals Inc, and Zomig Rapimelt 2.5 mg Orally Dispersible Tablet (DIN 02243045) manufactured by Astrazeneca Canada Inc., Sandoz Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02362996) manufactured by Sandoz Canada Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **December 3, 2018**, all claims for Sandoz Zolmitriptan ODT 2.5 mg Orally Dispersible Tablet (DIN 02362996) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at www.ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Methylphenidate 10 mg Tablet (DIN 02249324) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2019**.

METHYLPHENIDATE HCL

10 MG TABLET

| | | | |
|-------------|---------------------|-----|-----------|
| 00002249324 | APO-METHYLPHENIDATE | APX | \$ 0.0816 |
| 00000584991 | PMS-METHYLPHENIDATE | PMS | \$ 0.0816 |
| 00000005606 | RITALIN | NOV | \$ 0.3786 |

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril/HCTZ 20 mg/25 mg Tablet (DIN 02408783) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2019**.

QUINAPRIL/ HYDROCHLOROTHIAZIDE

20 MG / 25 MG TABLET

| | | | |
|-------------|--------------------|-----|-----------|
| 00002408783 | APO-QUINAPRIL/HCTZ | APX | \$ 0.6512 |
| 00002237369 | ACCURETIC 20/25 | PFI | \$ 0.9203 |

... continued from previous page

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) manufactured by Pharmascience Inc., Salazopyrin 500 mg Tablet (DIN 02064480) manufactured by Pfizer Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) has been resolved.

As a result, pms-Sulfasalazine 500 mg Tablet (DIN 00598461) will no longer be considered a temporary benefit for the *ADBL* after **January 3, 2018**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.773 2018/12

